ECYT News & Charts - Endocyte to resume patient enrollment in Proceed Phase 3 trial in the U.S. (ECYT) 3.49 : Co announced that the FDA has approved the importation of Endocyte's supply of Doxil from Europe into the U.S. for use in the PROCEED Phase 3 trial. The trial was initiated in May 2011 but enrollment stopped later in the year due to global shortages of Doxil. Endocyte plans to provide additional updates on clinical development plans as part of the fourth quarter earnings announcement and conference call in mid-March.
Market Data 
Markets 
AI
